Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues

International Journal of Pharmaceutics

Volumn 497, Issue 1-2, 2016, Pages 268-276

  Thao, Le Quang ^a   Byeon, Hyeong Jun ^a   Lee, Changkyu ^a   Lee, Seunghyun ^a   Lee, Eun Seong ^b   Choi, Han Gon ^c   Park, Eun Seok ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Albumin; Collagen induced arthritis; Nanoparticles; Rheumatoid arthritis; Tacrolimus; Targeting

Indexed keywords

HUMAN SERUM ALBUMIN; NANOCARRIER; TACROLIMUS; COLLAGEN; DRUG CARRIER; NANOPARTICLE; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DYNAMIC LIGHT SCATTERING; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT SCATTERING; MALE; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; T LYMPHOCYTE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JOINT; METABOLISM; SOLUBILITY; ULTRASTRUCTURE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; COLLAGEN; DRUG CARRIERS; DRUG LIBERATION; HUMANS; JOINTS; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN; SOLUBILITY; T-LYMPHOCYTES; TACROLIMUS;

EID: 84949571103     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.12.004     Document Type: Article

References (36)

1. S.M. Ali, A. Ahmad, S. Sheikh, M.U. Ahmad, R.C. Rane, P. Kale, M. Paithankar, D. Saptarishi, A. Sehgal, K. Maheshwari, and I. Ahmad Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant tacrolimus: pharmacokinetics, safety, and tolerability in rodents and humans Int. Immunopharmacol. 10 2010 325 330
2. S. Bae, K. Ma, T.H. Kim, E.S. Lee, K.T. Oh, E.S. Park, K.C. Lee, and Y.S. Youn Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types Biomaterials 33 2012 1536 1546
3. F.C. Ballantyne, A. Fleck, and W.C. Dick Albumin metabolism in rheumatoid arthritis Ann. Rheum. Dis. 30 1971 265 270
4. A.M. Bendele Animal models of rheumatoid arthritis J. Musculoskelet. Neuronal Interact. 1 2001 377 385
5. H.J. Byeon, S.Y. Min, I. Kim, E.S. Lee, K.T. Oh, B.S. Shin, K.C. Lee, and Y.S. Youn Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis Bioconjug. Chem. 25 2014 2212 2221
6. S.H. Choi, H.J. Byeon, J.S. Choi, L. Thao, I. Kim, E.S. Lee, B.S. Shin, K.C. Lee, and Y.S. Youn Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer J. Control. Release 197 2014 199 207
7. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin. Cancer Research 12 2006 1317 1324
8. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - new applications on the horizon J. Control. Release 157 2012 4 28
9. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
10. R. Fanciullino, J. Ciccolini, and G. Milano Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs Crit. Rev. Oncol. Hematol. 88 2013 504 513
11. Q. Fu, J. Sun, W. Zhang, X. Sui, Z. Yan, and Z. He Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery Recent Pat. Anticancer. Drug Discov. 4 2009 262 272
12. D.E. Furst, K. Saag, M.R. Fleischmann, Y. Sherrer, J.A. Block, T. Schnitzer, J. Rutstein, A. Baldassare, J. Kaine, L. Calabrese, F. Dietz, M. Sack, R.G. Senter, C. Wiesenhutter, M. Schiff, C.M. Stein, Y. Satoi, A. Matsumoto, J. Caldwell, R.E. Harris, L.W. Moreland, E. Hurd, D. Yocum, and D.A. Stamler Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study Arthritis Rheum. 46 2002 2020 2028
13. C. Jin, S.Y. Chae, T.H. Kim, H. Yang, E.Y. Lee, Y.W. Song, D. Jo, and K.C. Lee Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis Pharmacology 332 2010 858 865
14. K. Kannan, R.a. Ortmann, and D. Kimpel Animal models of rheumatoid arthritis and their relevance to human disease Pathophysiology 12 2005 167 181
15. I. Kim, H.J. Byeon, T.H. Kim, E.S. Lee, K.T. Oh, B.S. Shin, K.C. Lee, and Y.S. Youn Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer Biomaterials 34 2013 6444 6453
16. I. Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, and Y.S. Youn Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy Bioconjug. Chem. 21 2010 1513 1519
17. T.H. Kim, H.H. Jiang, Y.S. Youn, C.W. Park, K.K. Tak, S. Lee, H. Kim, S. Jon, X. Chen, and K.C. Lee Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity Int. J. Pharm. 403 2011 285 291
18. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
19. F. Kratz, and A. Warnecke Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems J. Control. Release 164 2012 221 235
20. S.-K. Kwok, M.-K. Park, M.-L. Cho, H.-J. Oh, E.-M. Park, D.-G. Lee, J. Lee, H.-Y. Kim, and S.-H. Park Retinoic acid attenuates rheumatoid inflammation in mice J. Immunol. 189 2012 1062 1071
21. E. Letko, K. Bhol, V. Pinar, C.S. Foster, and R. Ahmed a Tacrolimus (FK 506) Ann. Allergy Asthma Immunol. 83 1999 179 189 quiz 189-190
22. R. Levick Permeability of rheumatoid and normal human synovium to specific plasma proteins Arthritis Rheum. 24 1981 1550 1560
23. G. Li, C. Fan, X. Li, Y. Fan, X. Wang, M. Li, and Y. Liu Preparation and in vitro evaluation of tacrolimus-loaded ethosomes Sci. World J. 1 2012 1 6
24. K. Magari, F. Nishigaki, T. Sasakawa, T. Ogawa, S. Miyata, Y. Ohkubo, S. Mutoh, and T. Goto Anti-arthritic properties of FK506 on collagen-induced arthritis in rats Inflamm. Res. 52 2003 524 529
25. S.Y. Min, H.J. Byeon, C. Lee, J. Seo, E.S. Lee, B.S. Shin, H.-G. Choi, K.C. Lee, and Y.S. Youn Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer Int. J. Pharm. 494 2015 506 515
26. G.S. Panayi, J.S. Lanchbury, and G.H. Kingsley The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis Arthritis Rheum. 35 1992 729 735
27. P. Patel, H. Patel, S. Panchal, and T. Mehta Formulation strategies for drug delivery of tacrolimus: an overview Int. J. Pharm. Investig. 2 2012 169 175
28. H. Sage, C. Johnson, and P. Bornstein Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture J. Biol. Chem. 259 1984 3993 4007
29. S. Sakuma, Y. Kato, F. Nishigaki, T. Sasakawa, K. Magari, S. Miyata, Y. Ohkubo, and T. Goto FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells Br. J. Pharmacol. 130 2000 1655 1663
30. C.M. Spencer, K.L. Goa, and J.C. Gillis Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation Drugs 54 1997 925 975
31. G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, S. Schütt, W. Maier-Borst, and D.L. Heene The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats Anticancer Drugs 8 1997 677 685
32. M.J. Tocci, D.A. Matkovich, K.A. Collier, P. Kwok, F. Dumont, S. Lin, S. Degudicibus, J.J. Siekierka, J. Chin, and N.I. Hutchinson The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes J. Immunol. 143 1989 718 726
33. P. Wilkinson, R. Jeremy, F.P. Brooks, and J.L. Hollander The mechanism of hypoalbuminemia in rheumatoid arthritis Ann. Intern. Med. 63 1965 109 114
34. A. Wunder, U. Müller-Ladner, E.H.K. Stelzer, J. Funk, E. Neumann, G. Stehle, T. Pap, H. Sinn, S. Gay, and C. Fiehn Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis J. Immunol. 170 2003 4793 4801
35. S. Yoshino, E. Sasatomi, Y. Mori, and M. Sagai Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice J. Immunol. 163 1999 3417 3422
36. L. Zhao, Y. Zhou, Y. Gao, S. Ma, C. Zhang, J. Li, D. Wang, X. Li, C. Li, Y. Liu, and X. Li Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity Int. J. Pharm. 483 2015 180 187